Class information for:
Level 1: GLIOBLASTOMA//TUMOR TREATING FIELDS//BEVACIZUMAB

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
11787 954 51.8 88%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
6 4 GASTROENTEROLOGY & HEPATOLOGY//ONCOLOGY//SURGERY 1371034
329 3       MENINGIOMA//NEUROSURG//JOURNAL OF NEURO-ONCOLOGY 38091
102 2             GLIOBLASTOMA//GLIOMA//MEDULLOBLASTOMA 25713
11787 1                   GLIOBLASTOMA//TUMOR TREATING FIELDS//BEVACIZUMAB 954

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 GLIOBLASTOMA authKW 617716 36% 6% 344
2 TUMOR TREATING FIELDS authKW 423608 2% 88% 15
3 BEVACIZUMAB authKW 412181 24% 6% 226
4 NEUROONCOL address 277173 15% 6% 146
5 RECURRENT GLIOBLASTOMA authKW 257538 3% 31% 26
6 TUMOR TREATING FIELDS TTFIELDS authKW 192037 1% 100% 6
7 STEPHEN E CATHERINE P PAS NEUROONCOL address 180508 2% 30% 19
8 DEVELOPMENTS IN ONCOLOGY journal 143772 8% 6% 75
9 NOVOTTF 100A authKW 133358 1% 83% 5
10 MALIGNANT GLIOMA authKW 132704 7% 6% 64

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 Oncology 19120 72% 0% 687
2 Clinical Neurology 6184 35% 0% 338
3 Pharmacology & Pharmacy 127 9% 0% 89
4 Pathology 77 3% 0% 31
5 Radiology, Nuclear Medicine & Medical Imaging 66 5% 0% 43
6 Cell Biology 53 6% 0% 57
7 Medicine, Research & Experimental 37 4% 0% 34
8 Neurosciences 33 6% 0% 59
9 Neuroimaging 21 1% 0% 7
10 Surgery 6 4% 0% 37

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 NEUROONCOL 277173 15% 6% 146
2 STEPHEN E CATHERINE P PAS NEUROONCOL 180508 2% 30% 19
3 NEUROONCOL BRANCH 116939 3% 15% 25
4 P TON ROBERT TI BRAIN TUMOR 100986 3% 13% 25
5 CANC NEUROL 92245 1% 41% 7
6 NEUROONCOL UNIT 65007 2% 10% 21
7 DIAGNOST IMAGING INTERVENT ONCOL UNIT 64012 0% 100% 2
8 JOHNNIE L COCHRAN JR BRAIN TUMOR 64012 0% 100% 2
9 NEUROONCOL PROGRAMSIRIRAJ HOSP 64012 0% 100% 2
10 SERV NEUROONCOL 58177 1% 18% 10

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 DEVELOPMENTS IN ONCOLOGY 143772 8% 6% 75
2 JOURNAL OF NEURO-ONCOLOGY 70560 11% 2% 109
3 NEURO-ONCOLOGY 50201 2% 8% 19
4 EXPERT REVIEW OF NEUROTHERAPEUTICS 5293 1% 1% 13
5 BRAIN TUMOR PATHOLOGY 4782 1% 2% 7
6 EXPERT REVIEW OF ANTICANCER THERAPY 3274 1% 1% 13
7 CLINICAL CANCER RESEARCH 2448 4% 0% 34
8 CURRENT TREATMENT OPTIONS IN ONCOLOGY 2170 1% 1% 5
9 CURRENT OPINION IN NEUROLOGY 1935 1% 1% 11
10 ONCOLOGIST 1733 1% 0% 11

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class		 LCSH search Wikipedia search
1 GLIOBLASTOMA 617716 36% 6% 344 Search GLIOBLASTOMA Search GLIOBLASTOMA
2 TUMOR TREATING FIELDS 423608 2% 88% 15 Search TUMOR+TREATING+FIELDS Search TUMOR+TREATING+FIELDS
3 BEVACIZUMAB 412181 24% 6% 226 Search BEVACIZUMAB Search BEVACIZUMAB
4 RECURRENT GLIOBLASTOMA 257538 3% 31% 26 Search RECURRENT+GLIOBLASTOMA Search RECURRENT+GLIOBLASTOMA
5 TUMOR TREATING FIELDS TTFIELDS 192037 1% 100% 6 Search TUMOR+TREATING+FIELDS+TTFIELDS Search TUMOR+TREATING+FIELDS+TTFIELDS
6 NOVOTTF 100A 133358 1% 83% 5 Search NOVOTTF+100A Search NOVOTTF+100A
7 MALIGNANT GLIOMA 132704 7% 6% 64 Search MALIGNANT+GLIOMA Search MALIGNANT+GLIOMA
8 NOVOTTF 100A SYSTEM 128025 0% 100% 4 Search NOVOTTF+100A+SYSTEM Search NOVOTTF+100A+SYSTEM
9 TTFIELDS 100016 1% 63% 5 Search TTFIELDS Search TTFIELDS
10 PERITUMOR TISSUE 96019 0% 100% 3 Search PERITUMOR+TISSUE Search PERITUMOR+TISSUE

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref.
in cl.		 Shr. of ref. in
cl.		 Citations
1 BATCHELOR, TT , REARDON, DA , DE GROOT, JF , WICK, W , WELLER, M , (2014) ANTIANGIOGENIC THERAPY FOR GLIOBLASTOMA: CURRENT STATUS AND FUTURE PROSPECTS.CLINICAL CANCER RESEARCH. VOL. 20. ISSUE 22. P. 5612 -5619 63 70% 22
2 HAMZA, MA , GILBERT, M , (2014) TARGETED THERAPY IN GLIOMAS.CURRENT ONCOLOGY REPORTS. VOL. 16. ISSUE 4. P. - 85 51% 10
3 FIELD, KM , JORDAN, JT , WEN, PY , ROSENTHAL, MA , REARDON, DA , (2015) BEVACIZUMAB AND GLIOBLASTOMA: SCIENTIFIC REVIEW, NEWLY REPORTED UPDATES, AND ONGOING CONTROVERSIES.CANCER. VOL. 121. ISSUE 7. P. 997 -1007 46 73% 16
4 CHINOT, OL , REARDON, DA , (2014) THE FUTURE OF ANTIANGIOGENIC TREATMENT IN GLIOBLASTOMA.CURRENT OPINION IN NEUROLOGY. VOL. 27. ISSUE 6. P. 675 -682 44 71% 4
5 KHASRAW, M , AMERATUNGA, M , GROMMES, C , (2014) BEVACIZUMAB FOR THE TREATMENT OF HIGH-GRADE GLIOMA: AN UPDATE AFTER PHASE ILL TRIALS.EXPERT OPINION ON BIOLOGICAL THERAPY. VOL. 14. ISSUE 5. P. 729 -740 41 65% 16
6 ZHAO, G , ZHANG, ZH , LI, YQ , CHEN, Y , WANG, N , ZHAO, ZY , XIE, GF , YU, ZY , (2016) EFFICACY AND SAFETY OF BEVACIZUMAB FOR THE TREATMENT OF GLIOBLASTOMA (REVIEW).EXPERIMENTAL AND THERAPEUTIC MEDICINE. VOL. 11. ISSUE 2. P. 371 -380 37 73% 1
7 NARITA, Y , (2015) BEVACIZUMAB FOR GLIOBLASTOMA.THERAPEUTICS AND CLINICAL RISK MANAGEMENT. VOL. 11. ISSUE . P. 1759 -1765 40 67% 5
8 WANG, HX , XU, T , JIANG, Y , XU, HC , YAN, Y , FU, D , CHEN, JX , (2015) THE CHALLENGES AND THE PROMISE OF MOLECULAR TARGETED THERAPY IN MALIGNANT GLIOMAS.NEOPLASIA. VOL. 17. ISSUE 3. P. 239 -255 62 37% 15
9 RINNE, ML , LEE, EQ , NAYAK, L , NORDEN, AD , BEROUKHIM, R , WEN, PY , REARDON, DA , (2013) UPDATE ON BEVACIZUMAB AND OTHER ANGIOGENESIS INHIBITORS FOR BRAIN CANCER.EXPERT OPINION ON EMERGING DRUGS. VOL. 18. ISSUE 2. P. 137 -153 63 43% 17
10 POULSEN, HS , URUP, T , MICHAELSEN, SR , STABERG, M , VILLINGSHOJ, M , LASSEN, U , (2014) THE IMPACT OF BEVACIZUMAB TREATMENT ON SURVIVAL AND QUALITY OF LIFE IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS.CANCER MANAGEMENT AND RESEARCH. VOL. 6. ISSUE . P. 373 -387 50 52% 12

Classes with closest relation at Level 1


Rank Class id link
1 1424 TEMOZOLOMIDE//GLIOBLASTOMA//GLIOBLASTOMA MULTIFORME
2 6545 EGFRVIII//EGFR AMPLIFICATION//GLIOBLASTOMA
3 3078 PSEUDOPROGRESSION//MAGNETIC RESONANCE SPECTROSCOPY//PERFUSION MRI
4 32191 ENZASTAURIN//LY317615//INTRATUMORAL VESSELS
5 2763 OLIGODENDROGLIOMA//IDH1//OLIGOASTROCYTOMA
6 17795 TCD50//TUMOR BED EFFECT//ONCORAY RADIAT
7 19370 VASCULOGENIC MIMICRY//TIANJIN CANC HOSP//TUMOR ENDOTHELIAL CELLS
8 18265 VANDETANIB//NINTEDANIB//CEDIRANIB
9 27032 VESSEL SIZE IMAGING//VESSEL SIZE INDEX//DIFFUSION DEPHASING
10 7512 GLIOMA//GL261//BRAIN TUMOR PROGRAM

Go to start page